Fe3 has developed a novel transdermal patch for the treatment of iron-deficiency anemia, one of the world's most prevalent micro-nutrient deficiencies. Roughly a third of the US population suffers from some form of anemia, and the condition is still under-diagnosed and under-treated. Millions of people, mainly women, suffer from a variety of undesirable consequences including fatigue, poor cognition, and defects in motor function. The Fe3 patch offers an alternative to oral iron for the nearly half of patients who cannot tolerate gastrointestinal side effects of iron pills such as constipation, diarrhea, nausea and bloating. A non-invasive, overnight, once-a-week patch, the Fe3 solution is easy-to-use by the patient at home.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
03/03/16 | $11,000,000 | Series B |
HG Capital Jianmin Pharmaceuticals Ping An Ventures | undisclosed |